Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Sexovid(F 6066)ÀÇ ÛÉÕ° ¹× ìõããë¯Û¡üùÍý¿¡ μÇÑ ìúßÉîÜ Ëþ÷Ð

Clinical Evaluation of the Ovulation and Pregnancy Inducing Action of Sexovid

´ëÇÑ»êºÎÀΰúÇÐȸÁö 1970³â 13±Ç 2È£ p.3 ~ 7
ãéê©ûÇ, ì°ßÓëÃ,
¼Ò¼Ó »ó¼¼Á¤º¸
ãéê©ûÇ (  ) - ½Å¿õÈ£ »êºÎÀΰú ÀÇ¿ø
ì°ßÓëà(  ) - ùÛìéÜ»ê ߧÜþìÑΡ

Abstract


The capacity of Sexovid(F6066) to induce ovulation and pregnancy in cases of anovulatory menses and aInenorrhea (1st and 2nd grade) was evaluated in 17 patients. Nine cases (52.9%) ovulated and five cases(29066) conceived; i.e., in 11 patients with anovulatory cycles, five cases ovulated and 3cases became pregnant, in 2 cases with first grade amenorrhea all conceived, in 4 ¡×cases with second ,grade amenorrhea 2cases ovulated.
The optimum dose of Sexovid was found to be 200-400mg daily for 7-10 days each month. The complication of therapy, was amenorrhea continuing for 2-3 months after administration un 5cases o anovu atorymenses.
In addition to 18 patients , with ovulatory infertility, were evaluated. Seven pregnancies occurred.

The administration of Sexovid (100mg daily for 5-6days each month) appears to be useful therapeutic approach to the problem of ,patients with ovulatory infertility.

Ű¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS